TAK News
Takeda Pharmaceutical Company Limited
$20.15
-$0.12(-0.59%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
--
Volume
3.12M
52W Range
$12.99 - $19.89
Target Price
--
TAK news: the latest Takeda Pharmaceutical Company Limited headlines, press releases and market updates, newest first.
Latest TAK News
- Takeda’s Mobocertinib Trial Update: What Lung Cancer Data Mean for TAK InvestorsTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 28, 2026
- Atakey Patates Nears 1% Capital Threshold in Ongoing Share Buyback ProgramTipRanks Turkey Auto-Generated Newsdesk · Oct 27, 2026
- Atakey Patates Gida Releases Nine-Month 2026 Summary FinancialsTipRanks Turkey Auto-Generated Newsdesk · Oct 26, 2026
- Atakey Patates Details Nine-Month Operating Review and Governance FocusTipRanks Turkey Auto-Generated Newsdesk · Oct 26, 2026
- Atakey Patates Continues Share Buybacks, Reaches 0.91% of CapitalTipRanks Turkey Auto-Generated Newsdesk · Oct 22, 2026
- Atakey Patates Expands Share Buyback, Reaches 0.81% of CapitalTipRanks Turkey Auto-Generated Newsdesk · Oct 20, 2026
- Atakey Patates Expands Multi-Year Share Buyback, Lifts Repurchased Stake to 0.78%TipRanks Turkey Auto-Generated Newsdesk · Oct 19, 2026
- Atakey Patates Sets Date for Nine-Month 2026 Financial ResultsTipRanks Turkey Auto-Generated Newsdesk · Oct 16, 2026
- Desjardins Keeps Their Buy Rating on Volatus Aerospace (TAKOF)TipRanks Auto-Generated Intelligence Newsdesk · Oct 15, 2026
- Borsa Istanbul Halts Continuous Trading in Atakey Patates Gida SharesTipRanks Turkey Auto-Generated Newsdesk · Oct 12, 2026
- Takeda Advances Pediatric Vedolizumab Trial, Strengthening Its IBD Growth StoryTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 9, 2026
- STAK Inc. Shareholders Approve Major Capital Restructuring and Voting Rights ChangeTipRanks Auto-Generated Newsdesk · Oct 9, 2026
- Takeda’s CDPATH™ Study Signals Growing Focus on Data‑Driven Crohn’s CareTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?Ran Melamed · Oct 7, 2026
- Atakey Patates Gida Strengthens Board and Governance StructureTipRanks Turkey Auto-Generated Newsdesk · Oct 7, 2026
- Atakey Patates strengthens board and governance structure with new independent membersTipRanks Turkey Auto-Generated Newsdesk · Oct 6, 2026
- ASCE GMYO Added to Borsa Istanbul Buyback Index in October ReviewTipRanks Turkey Auto-Generated Newsdesk · Oct 5, 2026
- Upcoming Stock Splits This Week (October 5–9) – Stay InvestedBen Yoffe · Oct 4, 2026
- Catheter Precision Plans Reverse Split and Flyte RebrandingTipRanks Auto-Generated Newsdesk · Oct 2, 2026
- Takeda Refines VPRIV Home Infusion Playbook With New EU SurveyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 1, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TAK | $20.15 | -0.6% | 3.12M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Takeda Pharmaceutical Company Limited Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW